# Use of a Novel Artificial Intelligence Assisted Platform to Assess Optimal Dosing and Treatment Strategy of Erythropoiesis-stimulating Agents (ESA) in Hemodialysis Patients

Study · id `cardio:ct-nct05032651` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05032651](<https://clinicaltrials.gov/study/NCT05032651>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05032651

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 130 participants.

## Technical summary

Registry record NCT05032651. Randomized; double masking; primary purpose health services research. Start 2021-03-19 (actual); primary completion 2023-12-23 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose health services research
- Phase: Not applicable
- Enrolled: 130 participants (planned count; ClinicalTrials.gov record NCT05032651, source copy `cardio:ctgov-nct05032651-2021-10-13`, retrieved 2026-10-26)
- Started: 2021-03-19 (actual) (ClinicalTrials.gov record NCT05032651, source copy `cardio:ctgov-nct05032651-2021-10-13`, retrieved 2026-10-26)
- Primary completion: 2023-12-23 (anticipated) (ClinicalTrials.gov record NCT05032651, source copy `cardio:ctgov-nct05032651-2021-10-13`, retrieved 2026-10-26)
- Completion: 2023-12-23 (anticipated) (ClinicalTrials.gov record NCT05032651, source copy `cardio:ctgov-nct05032651-2021-10-13`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT05032651, source copy `cardio:ctgov-nct05032651-2021-10-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05032651-2021-10-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Use of a Novel Artificial Intelligence Assisted Platform to Assess Optimal Dosing and Treatment Strategy of Erythropoiesis-stimulating Agents (ESA) in Hemodialysis Patients
- Acronym: AI
- Condition: End Stage Renal Disease on Dialysis
- Intervention (Device): novel artificial intelligence assisted platform
- Lead sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
- Lead sponsor class: OTHER
- Collaborator: National Sun Yat-sen University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital (`cardio:org-kaohsiung-medical-university-chung-ho-memorial-hospital`)

## Provenance

Content hash: 18e3665391db8f8c9f58bab6c97ad7895da273fb968090598a617843d4e6376b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
